Kesimpta More Cost-Effective for RRMS & Following My Own (MS) Advice. episode artwork

EPISODE · Oct 5, 2022 · 11 MIN

Kesimpta More Cost-Effective for RRMS & Following My Own (MS) Advice.

from MS News & Perspectives · host MS News Today

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads a new analysis regarding the fact that in Canada, Kesimpta is more cost-effective than other DMTs for treating relapsing-remitting MS.He also reads “My Wife Says I Should Follow My Own (MS) Advice” by Ed Tobias, from his column “The MS Wire”. =================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/=====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/

Episode metadata supplied by the publisher feed · Published Oct 5, 2022

Embed this episode

NOW PLAYING

Kesimpta More Cost-Effective for RRMS & Following My Own (MS) Advice.

0:00 11:42

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MS News & Perspectives?

This episode is 11 minutes long.

When was this MS News & Perspectives episode published?

This episode was published on October 5, 2022.

Can I download this MS News & Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!